XFOR - X4 Pharmaceuticals Inc Stock Price, Fair Value and News

$0.610.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

XFOR Price Action

Last 7 days

-9.0%

Last 30 days

79.4%

Last 90 days

-14.1%

Trailing 12 Months

-17.6%

XFOR RSI Chart

XFOR Valuation

Market Cap

104.0M

Price/Earnings (Trailing)

-6.21

Price/Sales (Trailing)

38.09

EV/EBITDA

-0.86

Price/Free Cashflow

-0.99

XFOR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XFOR Fundamentals

XFOR Revenue

Revenue (TTM)

3.0M

XFOR Earnings

Earnings (TTM)

-16.8M

Earnings Growth (Yr)

-1.5K%

Earnings Growth (Qtr)

-140.4%

XFOR Profitability

Operating Margin

83.50%

EBT Margin

-555.80%

Return on Equity

-28.11%

Return on Assets

-9.41%

Free Cashflow Yield

-101.16%

XFOR Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-0.07

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2020	5.7M	5.2M	3.2M	3.0M
2018	3.6M	3.3M	3.7M	3.2M
2017	2.8M	3.1M	3.5M	3.9M
2016	0	0	0	2.4M
2015	0	0	0	2.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and WaldenstrÃƒÆ’Ã‚Â¶m macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

CEO	Dr. Paula Ragan Ph.D.
WEBSITE	x4pharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	40

X4 Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for X4 Pharmaceuticals Inc? What does XFOR stand for in stocks?

XFOR is the stock ticker symbol of X4 Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of X4 Pharmaceuticals Inc (XFOR)?

As of Fri Dec 20 2024, market cap of X4 Pharmaceuticals Inc is 104.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XFOR stock?

You can check XFOR's fair value in chart for subscribers.

Is X4 Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XFOR is over valued or under valued. Whether X4 Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact X4 Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XFOR.

What is X4 Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, XFOR's PE ratio (Price to Earnings) is -6.21 and Price to Sales (PS) ratio is 38.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XFOR PE ratio will change depending on the future growth rate expectations of investors.